The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
6 p.m. CT Friday, June 12
On behalf of my colleagues Mason Freeman, Joseph Massaro, Scott Solomon, J Paul Lock, Mathew Riddle, John Parker, Eldrin Lewis and Yuan-Di Halvorsen, and our team of investigators, I will present the results of the Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial. Bexagliflozin is a potent and highly specific inhibitor of SGLT2, which we compared to placebo in 1,700 patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. We studied the efficacy of bexagliflozin 20 mg once daily in controlling hyperglycemia, weight and blood pressure, and the safety of bexagliflozin, including cardiovascular outcomes. This is the first presentation of the results of BEST.
VIEW THIS PRESENTATION
Already registered?
View this presentation at ADA2020.org.
Not yet registered?
Register now to access all presentations from the Virtual 80th Scientific Sessions.